Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Dawson

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Antimicrobial Chemotherapy|August 5, 2020
Clofazimine pharmacokinetics in patients with TB: dosing implicationsMahmoud Tareq Abdelwahab, Sean Wasserman, James C M Brust, et al.
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
The Journal of Infectious Diseases|April 1, 2024
Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized TrialDereck Tait, Andreas Diacon, Álvaro H Borges, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
Plos One|March 12, 2009
Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden settingKeertan Dheda, Richard N Van-Zyl Smit, Leonardo A Sechi, et al.
The Lancet. Infectious Diseases|May 29, 2026
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trialRodney Dawson, Andreas H Diacon, Ebrahim Variava, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsAndreas H Diacon, Rodney Dawson, Madeleine Hanekom, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of RifapentineJose Francis, Simbarashe P Zvada, Paolo Denti, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|August 5, 2020
Clofazimine pharmacokinetics in patients with TB: dosing implicationsMahmoud Tareq Abdelwahab, Sean Wasserman, James C M Brust, et al.
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
The Journal of Infectious Diseases|April 1, 2024
Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized TrialDereck Tait, Andreas Diacon, Álvaro H Borges, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
Plos One|March 12, 2009
Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden settingKeertan Dheda, Richard N Van-Zyl Smit, Leonardo A Sechi, et al.
The Lancet. Infectious Diseases|May 29, 2026
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trialRodney Dawson, Andreas H Diacon, Ebrahim Variava, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsAndreas H Diacon, Rodney Dawson, Madeleine Hanekom, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of RifapentineJose Francis, Simbarashe P Zvada, Paolo Denti, et al.
Pageof 10